Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 09:06 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effect of Montelukast Therapy in Obstructive Sleep Apnea(OSA) Children
NCT01027806 · University of Chicago · PHASE4 · terminated · last registry update 2019-05-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Poor accrual” | – | Registry record, University of Chicago |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CYSLTR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-04-17Phase 3 first posted: Great Ormond Street Hospital for Children NHS Foundation Trust, Montelukast (NCT04351698)
- 2020-03-27Phase 3 first posted: Hanmi Pharmaceutical Company Limited, HCP1102 + HGP1408 (NCT04324918)
- 2020-02-20Phase 3 first posted: Jagiellonian University, Montelukast 10mg + Standard anti-platelet treatment (NCT04277702)
- 2020-02-17Phase 3 first posted: Sanofi, Isatuximab SAR650984 + Lenalidomide (NCT04270409)
- 2019-12-18Also stopped (terminated): Brighton and Sussex University Hospitals NHS Trust, Montelukast or Salmeterol or Theophylline or Steroid (NCT03269318)
- 2019-10-02Results posted on the registry: Memorial Sloan Kettering Cancer Center, carboplatin + carboplatin (NCT01248962)
- 2019-10-01Results posted on the registry: University of California, San Francisco, zafirlukast (NCT02950480)
- 2019-10-01Also stopped (terminated): University of California, San Francisco, zafirlukast (NCT02950480)
- 2019-08-28Also stopped (withdrawn): Medical College of Wisconsin, Montelukast + Fluticasone (NCT01702701)
- 2019-07-12Results posted on the registry: Menarini International Operations Luxembourg SA, Bilastine 20mg + Montelukast 10mg (NCT02761252)
- 2019-03-26Results posted on the registry: Vanderbilt University Medical Center, Montelukast added to Hydroxyurea + Placebo added to Hydroxyurea (NCT01960413)
- 2019-01-14Results posted on the registry: Maruho Europe Limited, Montelukast + ASP2151 (NCT02321748)
- 2018-12-10Phase 3 first posted: Sherief Abd-Elsalam, Rupatadine + Montelukast (NCT03770923)
- 2018-12-03Results posted on the registry: Romaker & Associates, budesonide and montelukast + Placebo (NCT01089647)
- 2018-11-23Results posted on the registry: Merck Sharp & Dohme LLC, MK-1029 + Placebo (NCT01624974)
- 2018-09-13Results posted on the registry: Merck Sharp & Dohme LLC, MK-1029 + Montelukast 10 mg (NCT01656395)
- 2018-09-13Also stopped (terminated): Merck Sharp & Dohme LLC, MK-1029 + Montelukast 10 mg (NCT01656395)
- 2018-08-28Results posted on the registry: Merck Sharp & Dohme LLC, MK-1029 150 mg + MK-1029 Matching-image Placebo (NCT02720081)
- 2018-07-24Results posted on the registry: Biogen, dimethyl fumarate + montelukast (NCT02410278)
- 2018-07-23Results posted on the registry: UCB S.A. - Pharma Sector, Placebo + Montelukast (NCT00295022)
- 2018-06-06Phase 3 first posted: University Hospital, Grenoble, Montelukast 10mg + Placebo (NCT03545997)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision